Literature DB >> 22553112

Outcome of fibrillary glomerulonephritis.

Stefan A Kalbermatter1, Claudio Marone, Donatella Casartelli, Martin Hausberg, Giovanni Banfi, Michael Mihatsch, Michael Dickenmann.   

Abstract

QUESTIONS UNDER STUDY: We assessed the long-term follow up of all the patients with fibrillary glomerulonephritis diagnosed since 1992 at our centre of reference for renal pathology in Basel.
METHODS: We performed a retrospective surveillance study with mail questionnaire based follow-up of all patients with the diagnosis of fibrillary glomerulonephritis found in the database of the department of renal pathology in Basel from 1992 to 2007. The outcome was assessed in terms of endstage renal disease (ESRD), death, reduction of proteinuria and improvement of estimated glomerular filtration rate (eGFR).
RESULTS: We obtained sufficient follow up data from 16 out of 20 identified patients. The mean follow up time was 35 months (1-115.1). Six patients died (37.5%), three without having ESRD. Six patients (37.5%) reached ESRD, five of them went on hemodialysis. Thirteen patients (81.3%) received an immunosuppressive therapy with steroids, five of them in combination with cyclophosphamide. The group without immunosuppressive therapy was too small to compare the two groups. In relation to the histological pattern membranous glomerulonephritis (MGN) had a better outcome as compared to the other histological patterns.
CONCLUSIONS: FGN is a heterogeneous disease associated with significant risk of ESRD and mortality. The histological type of the glomerulonephritis may influence the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22553112     DOI: 10.4414/smw.2012.13578

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  6 in total

1.  DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN.

Authors:  Surendra Dasari; Mariam P Alexander; Julie A Vrana; Jason D Theis; John R Mills; Vivian Negron; Sanjeev Sethi; Angela Dispenzieri; W Edward Highsmith; Samih H Nasr; Paul J Kurtin
Journal:  J Am Soc Nephrol       Date:  2017-11-02       Impact factor: 10.121

2.  Complete remission of DnaJ homolog subfamily B member 9-positive fibrillary glomerulonephritis following steroid monotherapy in an elderly Japanese woman.

Authors:  Takahiro Uchida; Shuuhei Komatsu; Takashi Sakai; Aki Kojima; Sachiko Iwama; Kentaro Sugisaki; Takashi Oda
Journal:  CEN Case Rep       Date:  2021-03-03

3.  Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis.

Authors:  Fernanda Payan Schober; Meghan A Jobson; Caroline J Poulton; Harsharan K Singh; Volker Nickeleit; Ronald J Falk; J Charles Jennette; Patrick H Nachman; William F Pendergraft Iii
Journal:  Am J Nephrol       Date:  2017-02-04       Impact factor: 3.754

Review 4.  Fibrillary Glomerulonephritis and DnaJ Homolog Subfamily B Member 9 (DNAJB9).

Authors:  Nattawat Klomjit; Mariam Priya Alexander; Ladan Zand
Journal:  Kidney360       Date:  2020-07-08

5.  Characteristics of patients with coexisting DNAJB9-associated fibrillary glomerulonephritis and IgA nephropathy.

Authors:  Samar M Said; Alejandro Best Rocha; Anthony M Valeri; Mohamad Sandid; Anhisekh Sinha Ray; Mary E Fidler; Mariam Priya Alexander; Christopher P Larsen; Samih H Nasr
Journal:  Clin Kidney J       Date:  2020-12-05

6.  The occurrence or fibrillary glomerulonephritis in patients with diabetes mellitus may not be coincidental: a report of four cases.

Authors:  Fayna González-Cabrera; Fernando Henríquez-Palop; Ana Ramírez-Puga; Raquel Santana-Estupiñán; Celia Plaza-Toledano; Gloria Antón-Pérez; Silvia Marrero-Robayna; Davinia Ramírez-Medina; Roberto Gallego-Samper; Nicanor Vega-Díaz; Rafael Camacho-Galan; José C Rodríguez-Pérez
Journal:  Case Rep Med       Date:  2013-05-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.